Immuno-Biological Laboratories Co., Ltd. AI Stock Analysis
Want to see JP:4570 full AI Analyst Report?
Immuno-Biological Laboratories Co., Ltd. (4570) AI Stock Analysis
Immuno-Biological Laboratories Co., Ltd.
(TSE/TYO:4570)
The overall score of 81 is heavily driven by the company's stellar financial turnaround, characterized by massive improvements in profit margins, negligible debt, and robust free cash flow generation. Healthy short-term technical indicators and a reasonable valuation further bolster this strong score. Earnings call and corporate events data were omitted due to lack of recent information, with their weights redistributed proportionally to the remaining metrics.
Immuno-Biological Laboratories Co., Ltd. (4570) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 8.54B
- Dividend Yield
- 0.64%
- Average Volume (3M)
- 128.32K
- Price to Earnings (P/E)
- 23.5
- Beta (1Y)
- 1.11
- Revenue Growth
- 7.10%
- EPS Growth
- 17.17%
- Country
- Japan
- Employees
- 54
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Immuno-Biological Laboratories Co., Ltd. Business Overview & Revenue Model
Company Description
Immuno-Biological Laboratories Co., Ltd. (IBL) is a global entity dedicated to the research, development, production, and distribution of immunological reagents. The company's diverse offerings include ELISA assay kits designed for the precise quanti...
Immuno-Biological Laboratories Co., Ltd. Financial Statement Overview
Summary
Immuno-Biological Laboratories has executed a remarkable turnaround, transitioning from heavy net losses to robust profitability with an impressive 32.7% net margin. Negligible debt and excellent cash flow generation underscore a rock-solid financial foundation.
Income Statement
88Very PositiveBalance Sheet
85Very PositiveCash Flow
90Very Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.08B | 1.00B | 969.53M | 816.70M | 794.62M | 647.58M |
| Gross Profit | 777.51M | 700.28M | 628.34M | 517.29M | 526.71M | 376.70M |
| EBITDA | 368.36M | 299.82M | 226.55M | 128.11M | -279.54M | -127.50M |
| Net Income | 368.32M | 329.01M | 249.05M | 186.69M | -289.73M | -258.77M |
Balance Sheet | ||||||
| Total Assets | 2.23B | 2.16B | 1.85B | 1.62B | 1.43B | 1.71B |
| Cash, Cash Equivalents and Short-Term Investments | 907.94M | 989.47M | 825.73M | 734.14M | 614.16M | 508.35M |
| Total Debt | 171.81M | 177.09M | 204.23M | 235.98M | 234.99M | 234.00M |
| Total Liabilities | 338.30M | 311.75M | 332.03M | 354.25M | 355.72M | 336.99M |
| Stockholders Equity | 1.89B | 1.84B | 1.51B | 1.27B | 1.08B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 267.68M | 123.83M | 115.11M | 26.46M | -93.20M |
| Operating Cash Flow | 0 | 301.09M | 183.50M | 133.78M | 26.46M | -93.20M |
| Investing Cash Flow | 0 | -116.46M | -53.66M | -24.50M | 30.04M | -155.63M |
| Financing Cash Flow | 0 | -27.14M | -31.75M | 991.00K | 991.00K | 144.00M |
Immuno-Biological Laboratories Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4570, the sentiment is Negative. The current price of 917.00 is below the 20-day moving average (MA) of 1002.05, below the 50-day MA of 1079.00, and below the 200-day MA of 1212.73, indicating a bearish trend. The MACD of -37.04 indicates Positive momentum. The RSI at 36.62 is Neutral, neither overbought nor oversold. The STOCH value of 43.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4570.
Immuno-Biological Laboratories Co., Ltd. Peers Comparison
Overall Rating
- JP:457081Outperform
JP:497847Neutral
JP:777442Neutral
JP:777639Underperform
JP:459938Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4570 | 81Outperform | JPY 9.07B | 23.55 | ― | 0.64% | 7.10% | 17.17% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4978 | 47Neutral | JPY 12.29B | -23.75 | ― | ― | -8.23% | -48.10% |
| JP:7774 | 42Neutral | JPY 27.61B | -74.80 | ― | ― | 17.05% | 10.47% |
| JP:7776 | 39Underperform | JPY 6.78B | -5.83 | ― | ― | -56.16% | 3.12% |
| JP:4599 | 38Underperform | JPY 7.46B | -4.01 | ― | ― | ― | 4.85% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4570 | Immuno-Biological Laboratories Co., Ltd. | 917.00 | 69.63 | 8.22% | |
| JP:4599 | StemRIM Inc. | 117.00 | -161.00 | -57.91% | |
| JP:4978 | ReproCELL Inc. | 109.00 | -48.00 | -30.57% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 653.00 | 175.00 | 36.61% | |
| JP:7776 | CellSeed Inc. | 169.00 | -232.00 | -57.86% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 08, 2026